Buntanetap dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Buntanetap is a pill that cuts how much amyloid, tau and alpha-synuclein the brain makes, all at once. It is in an 850-person final-stage Alzheimer's study, with a symptom result due early in 2027.
Evidence grade for Buntanetap: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 1 completed trial, none stating how many people. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 1
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 0 people given it
1 effects reported, 1 wanted, by people using it, not a trial
Goal pages: Brain, memory and mood
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Buntanetap is a daily pill from Annovis Bio. It cuts how much of three harmful brain proteins your nerve cells make: amyloid, tau and alpha-synuclein. It is being tested in Alzheimer's. It is not approved.
What people take it for
- Slowing Alzheimer's.
- Slowing Parkinson's.
What studies in people showed
In an early study, 14 people with early Alzheimer's and 54 with early Parkinson's took it or a dummy pill. It was safe up to 80 mg a day. The Alzheimer's group scored better on two thinking tests. Fourteen people cannot settle anything. A final-stage study of 850 people is running. The symptom result is due early in 2027. Earlier Parkinson's results were mixed.
What people report
Reports, not study results
The good
- In the small study on this page, the Alzheimer's group scored better on two thinking tests.
The bad
- The study on this page says it was safe but gives no side effect details, and we have not collected user reports on this one yet.
Where these come from: Both lines are from the study on this page. We have not collected forum or user reports for this drug yet.
My bottom line
Fourteen people is a hint, not a result. The 850-person study will tell us. Wait for it.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Buntanetap has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Memory and thinkingno headcount stated · 1 study
35 of the 36 indexed goals have no study of any kind behind Buntanetap
No study in people, animals or cells on this page reports a result for these. That does not prove Buntanetap does nothing for them. It does mean anything you have heard about Buntanetap and one of these did not come from a study cited here.
Show full evidence
What is Buntanetap?
Buntanetap is a pill that cuts how much amyloid, tau and alpha-synuclein the brain makes, all at once. It is in an 850-person final-stage Alzheimer's study, with a symptom result due early in 2027.
Buntanetap, from Annovis Bio, slows the making of three harmful brain proteins, rather than clearing one of them after it builds up. In an early study, 14 people with early Alzheimer's and 54 with early Parkinson's took it or a dummy pill. It was safe up to 80 mg a day, and the Alzheimer's group scored better on two thinking tests. That study was far too small to be sure. A larger study that bridged the middle and final stages was published in 2026. The final-stage study, which confirmed Alzheimer's with a pTau217 blood test, finished signing up 850 people in July 2026. The symptom result is due in the first quarter of 2027, and the result on slowing the disease in 2028. Earlier Parkinson's results were mixed.
How does Buntanetap work?
It slows how cells read the instructions for APP, tau and alpha-synuclein. That lowers the levels of all three proteins.
The evidence, in charts
Fig. 1a · how many people
850people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| ClinicalTrials.gov NCT06709014 2026 | 850 | 100% |
The whole total is one study of 850. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 1 more study in people gives no headcount and is not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
All 2 sources here are studies in people.
- Study in people · done in people2100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2023 and 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- 337.4 Da
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
No amino acid sequence is on file for Buntanetap, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Study in people2026Buntanetap Phase 3 in early Alzheimer's disease
This trial is fully enrolled and has published nothing. 850 people with early Alzheimer's are taking part, with the symptom result due in 2027 and the question of whether the disease itself slows due in 2028. Enrolment is a milestone, not evidence. Everything claimed for buntanetap in Alzheimer's today rests on a much smaller earlier study.
850 patients enrolled; readouts 2027 and 2028.
- Study in people2023Buntanetap, a novel translational inhibitor of multiple neurotoxic proteins, proves to be safe and promising in both Alzheimer's and Parkinson's patients
The early signal was hopeful, and the study was far too small to trust. Fourteen people with early Alzheimer's and 54 with early Parkinson's took buntanetap or a dummy pill. The drug was safe up to 80 mg a day, and the Alzheimer's group scored better on two thinking tests. Here is the problem. Fourteen people cannot settle anything. This was an early look, and its job was to justify a bigger study.
Double-blind placebo-controlled study in 14 early Alzheimer's and 54 early Parkinson's patients. Buntanetap was safe and well tolerated up to 80 mg daily, with statistically significant improvement on ADAS-Cog11 and WAIS coding in the Alzheimer's group. Small and exploratory; this is the study that justified the Phase 3.
Common questions
Has Buntanetap been tested in people?
Yes. 0 people given it across 1 completed trial cited here, 0 of which found nothing. Buntanetap is a pill that cuts how much amyloid, tau and alpha-synuclein the brain makes, all at once. It is in an 850-person final-stage Alzheimer's study, with a symptom result due early in 2027.
What is the Buntanetap dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 1 completed trial, 0 people given it
Is Buntanetap FDA-approved?
Investigational; in final-stage studies
Is buntanetap an amyloid antibody?
No. It is a small molecule taken by mouth. It lowers how much amyloid, tau and alpha-synuclein nerve cells make.